Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Celldex Therapeutics, Inc. (CLDX) had Weighted-Average Shares Outstanding (Diluted) of 66.39M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.73M |
|
$-56.60M |
|
-- |
|
$0.73M |
|
$64.59M |
|
$-63.86M |
|
$7.26M |
|
$-56.60M |
|
$-56.60M |
|
$-56.60M |
|
$-56.60M |
|
$-56.60M |
|
$-56.60M |
|
$-63.86M |
|
$-64.67M |
|
66.39M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
66.39M |
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$648.40M |
|
$4.39M |
|
$44.00M |
|
$692.41M |
|
$32.96M |
|
-- |
|
$4.04M |
|
$37.00M |
|
$655.41M |
|
$628.22M |
|
$655.41M |
|
66.39M |
|
| Cash Flow Statement Financials | |
$-98.38M |
|
$92.80M |
|
$0.27M |
|
$28.36M |
|
$23.04M |
|
$-5.31M |
|
$18.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-8747.53% |
|
-8747.53% |
|
-- |
|
-7753.42% |
|
-7753.42% |
|
$-99.37M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
8.11 |
|
11.10 |
|
-8.64% |
|
-9.01% |
|
-8.17% |
|
-8.64% |
|
$9.87 |
|
$-1.50 |
|
$-1.48 |
|